世界の分子診断市場(~2026年):製品&サービス別(試薬、キット、PoC&卓上機器)、用途別(新型コロナウイルス感染症、肝炎、HAI、HIV、腫瘍、遺伝子検査)、技術別(PCR、NGS、ISH)、エンドユーザー別(病院、診断研究所)

◆英語タイトル:Molecular Diagnostics Market by Product & Service(Reagents, Kits, PoC & Tabletop Instruments), Application(COVID-19, Hepatitis, HAI, HIV, Oncology, Genetic Tests), Technology (PCR, NGS, ISH), End User (Hospitals, Diagnostic Labs)-Global Forecast to 2026
◆商品コード:MD2521
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2029年4月15日
◆ページ数:265
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は、世界の分子診断市場規模が2021年178億ドルから2026年318億ドルまで、年平均12.3%成長すると予測しています。本調査レポートでは、分子診断の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品&サービス別(試薬&キット、器具、サービス&ソフトウェア)分析、技術別(PCR、INAAT、DNAシーケンシング&次世代シーケンシング、ISH、DNAマイクロアレイ)分析、用途別(感染症診断、腫瘍検査、遺伝子検査、その他)分析、エンドユーザー別(診断研究所、病院&クリニック)分析、地域別分析、競争状況、企業情報などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の分子診断市場規模:製品&サービス別(試薬&キット、器具、サービス&ソフトウェア)
・世界の分子診断市場規模:技術別(PCR、INAAT、DNAシーケンシング&次世代シーケンシング、ISH、DNAマイクロアレイ)
・世界の分子診断市場規模:用途別(感染症診断、腫瘍検査、遺伝子検査、その他)
・世界の分子診断市場規模:エンドユーザー別(診断研究所、病院&クリニック)
・世界の分子診断市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global molecular diagnostics market size is projected to reach USD 31.8 billion by 2026 from USD 17.8 billion in 2021, at a CAGR of 12.3% during the forecast period.”
Market growth is driven by factors such as the increasing prevalence of infectious diseases and cancer, the rising funding for R&D, the increase in PoC testing devices and technological advancements. On the other hand, an unfavorable reimbursement scenario and the high cost of instruments is expected to limit market growth to a certain extent in the coming years.

“The reagents & kits accounted for the highest growth rate in the molecular diagnostics market, by product & service, during the forecast period”
The molecular diagnostics market is segmented into reagents & kits, instruments and other products. The reagents & kits segment accounted for the highest growth rate in the molecular diagnostics market in 2020. The requirement reagents & kits in large numbers compared to instruments is the main factor contributing to this segment’s high growth rate. This segment’s market growth can also be attributed to repeat purchases of reagents & kits compared to instruments.

“Infectious Disease Diagnostics segment accounted for the highest CAGR”
Based on the application, the molecular diagnostics market is segmented into infectious disease diagnostics, oncology testing, genetic tests and other applications. In 2020, the oncology testing segment accounted for the highest growth rate. Increasing incidence of cancer, technological advancements, and development of personalized medicine and companion diagnostic assays are the major factors driving this segment’s growth.

“Diagnostic Laboratories segment accounted for the highest CAGR”
Based on end-users, the molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics and other end users. In 2020, the diagnostic laboratories segment accounted for the highest growth rate. This can be attributed to increased test volume of infectious diseases and cancer and strengthening healthcare infrastructure for efficient disease diagnosis and treatment.

“Asia Pacific: The fastest-growing region molecular diagnostics market”
The global molecular diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as the government efforts to increase awareness about the early detection of diseases and regular health check-ups; continuously rising healthcare expenditure; increasing number of hospitals and diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan are driving the growth of the molecular diagnostics market in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35%
• By Designation: C-level – 30%, D-level – 20%, and Others – 50%
• By Region: North America – 36%, Europe – 25%, Asia Pacific – 27%, Latin America – 9% , and the Middle East & Africa – 3%

Lits of Companies Profiled in the Report:
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Hologic, Inc. (US)
• bioMérieux SA (France)
• Abbott Laboratories (US)
• QIAGEN (Netherlands)
• Thermo Fisher Scientific Inc. (US)
• Illumina Inc. (US)
• Siemens Healthineers AG (Germany)
• Danaher Corporation (US)
• Myriad Genetics Inc. (US)
• Agilent Technologies Inc. (US)
• Becton, Dickinson and Company (US)
• DiaSorin S.p.A (Italy)
• Grifols S.A. (Spain)
• Quidel Corporation(US)
• Genetic Signatures (Australia)
• MDxHealth, Inc. (US)
• Exact Sciences Corporation (US)
• Biocartis NV (Belgium)
• TBG Diagnostics Ltd. (Australia)
• GenMark Diagnostics Inc. (US)
• Luminex Corporation (US)
• HTG Molecular Diagnostics Inc. (US)
• Vela Diagnostics (Singapore)
• Amoy Diagnostics Co., Ltd. (China)
• Molbio Diagnostics Pvt. Ltd. (India)
• ELITechGroup (France)
• Savyon Diagnostics Ltd. (Israel)
• ABACUS Diagnostica Oy (Finland)
• geneOmbio Technologies Pvt. Ltd. (India)

Research Coverage:
This report provides a detailed picture of the global molecular diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall molecular diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities

【レポートの目次】

1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
FIGURE 1 INCLUSIONS & EXCLUSIONS 34
1.2.1 MARKETS COVERED 35
FIGURE 2 MOLECULAR DIAGNOSTICS MARKET 35
1.2.2 YEARS CONSIDERED FOR THE STUDY 36
1.3 CURRENCY 36
1.4 LIMITATIONS 36
1.5 STAKEHOLDERS 36
1.6 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.2 RESEARCH APPROACH 38
FIGURE 3 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 38
2.2.1 SECONDARY DATA 39
2.2.1.1 Key data from secondary sources 39
2.2.2 PRIMARY DATA 40
2.2.2.1 Key data from primary sources 40
2.2.2.2 Key industry insights 42
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 42
2.3 MARKET SIZE ESTIMATION 43
2.3.1 BOTTOM-UP APPROACH 43
FIGURE 5 MOLECULAR DIAGNOSTICS MARKET: BOTTOM-UP APPROACH 44
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 45
2.3.2 TOP-DOWN APPROACH 45
FIGURE 7 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH 45
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 46
FIGURE 8 DATA TRIANGULATION METHODOLOGY 46
2.5 ASSUMPTIONS FOR THE STUDY 47
2.6 COVID-19 HEALTH ASSESSMENT 47
2.7 COVID-19 ECONOMIC ASSESSMENT 48
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 48
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 48
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 50
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN
THE MOLECULAR DIAGNOSTICS MARKET 51
3 EXECUTIVE SUMMARY 52
FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION) 52
FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 53
FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 53
FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 54
FIGURE 15 MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 54
FIGURE 16 MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 55
4 PREMIUM INSIGHTS 56
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW 56
FIGURE 17 THE RISING ADOPTION OF POC DIAGNOSTICS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD 56
4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION) 57
FIGURE 18 THE REAGENTS & KITS SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT & SERVICE, IN 2021 57
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 57
FIGURE 19 THE PCR SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD 57
4.4 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 58
FIGURE 20 THE DIAGNOSTIC LABORATORIES SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE END USER MARKET DURING THE FORECAST PERIOD 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
FIGURE 21 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59
5.2.1 DRIVERS 60
5.2.1.1 The increasing prevalence of infectious diseases and cancer 60
5.2.1.2 Rising focus on R&D and funding in molecular diagnostics 60
5.2.1.3 Increasing awareness for early disease diagnosis in developing countries 61
5.2.1.4 Rising technological advancements in molecular diagnostics 61
5.2.1.5 Increasing use of PoC diagnostic tests 62
5.2.2 RESTRAINT 62
5.2.2.1 Unfavorable reimbursement scenario 62
5.2.2.2 The high cost of instruments 62
5.2.3 OPPORTUNITIES 63
5.2.3.1 The growing significance of companion diagnostics 63
5.2.3.2 Growth opportunities in emerging countries 63
5.2.4 CHALLENGES 64
5.2.4.1 Changing regulatory landscape 64
5.2.4.2 Operational barriers 64
5.2.4.3 The introduction of alternative technologies 64
5.2.5 COVID 19 IMPACT ANALYSIS 65
5.3 PRICING ANALYSIS 66
TABLE 1 PRICING ANALYSIS OF MOLECULAR DIAGNOSTIC PRODUCTS (2021) 66
5.4 PATENT ANALYSIS 67
5.5 VALUE CHAIN ANALYSIS 67
FIGURE 22 VALUE CHAIN ANALYSIS OF THE MOLECULAR DIAGNOSTICS MARKET 67
5.6 SUPPLY CHAIN ANALYSIS 68
FIGURE 23 SUPPLY CHAIN ANALYSIS 68
5.7 ECOSYSTEM ANALYSIS 69
5.8 PORTER’S FIVE FORCES ANALYSIS 70
FIGURE 24 PORTER’S FIVE FORCES ANALYSIS 70
5.8.1 THREAT FROM NEW ENTRANTS 70
5.8.2 THREAT FROM SUBSTITUTES 70
5.8.3 BARGAINING POWER OF BUYERS 71
5.8.4 BARGAINING POWER OF SUPPLIERS 71
5.8.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 71
5.9 PESTLE ANALYSIS 72
5.10 REGULATORY LANDSCAPE 73
5.10.1 NORTH AMERICA 73
5.10.1.1 US 73
5.10.1.2 Canada 73
5.10.2 EUROPE 73
5.10.3 ASIA PACIFIC 73
5.10.3.1 China 73
5.10.3.2 Japan 74
5.10.3.3 India 74
5.10.4 LATIN AMERICA 74
5.10.4.1 Brazil 74
5.10.4.2 Mexico 74
5.10.5 MIDDLE EAST 75
5.10.6 AFRICA 75
5.11 TRADE ANALYSIS 75
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 75
5.11.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million) 75
5.11.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons) 76
5.12 TECHNOLOGY ANALYSIS 76
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 77
6.1 INTRODUCTION 78
TABLE 2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 78
6.2 REAGENTS & KITS 78
6.2.1 THE RECURRENT PURCHASE OF REAGENTS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH 78
TABLE 3 REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION) 79
6.3 INSTRUMENTS 79
TABLE 4 INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 79
TABLE 5 INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION) 80
6.3.1 TABLETOP INSTRUMENTS 80
6.3.1.1 The outbreak of COVID-19 and rising incidences of cancer drives the growth of this segment 80
TABLE 6 TABLETOP INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION) 81
6.3.2 PORTABLE & POC INSTRUMENTS 81
6.3.2.1 The increasing adoption of PoC technologies drives the growth of this segment 81
TABLE 7 PORTABLE & POC INSTRUMENTS MARKET, BY REGION,
2019–2026 (USD MILLION) 82
6.4 SERVICES & SOFTWARE 82
6.4.1 THE GROWING UPTAKE OF ADVANCED INSTRUMENTS IN THE MOLECULAR DIAGNOSTICS MARKET DRIVES SEGMENT GROWTH 82
TABLE 8 SERVICES & SOFTWARE MARKET, BY REGION, 2019–2026 (USD MILLION) 83
7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 84
7.1 INTRODUCTION 85
TABLE 9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 85
7.2 POLYMERASE CHAIN REACTION (PCR) 85
7.2.1 THE GROWING USE OF PCR IN PROTEOMICS AND GENOMICS IS A MAJOR GROWTH DRIVER FOR THIS SEGMENT 85
TABLE 10 PCR TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION) 86
7.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 86
7.3.1 THE COST-BENEFITS OF THIS TECHNOLOGY IS A KEY FACTOR DRIVING THE MARKET GROWTH 86
TABLE 11 INAAT TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION) 87
7.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 87
7.4.1 INCREASING USE OF NGS IN THE DIAGNOSIS OF CANCER IS A GROWTH DRIVER FOR THIS SEGMENT 87
TABLE 12 DNA SEQUENCING & NGS TECHNOLOGY MARKET, BY REGION,
2019–2026 (USD MILLION) 88

7.5 IN SITU HYBRIDIZATION (ISH) 89
7.5.1 THE RISING PREVALENCE OF CANCER AND GENETIC DISORDERS IS A KEY FACTOR DRIVING SEGMENT GROWTH 89
TABLE 13 ISH TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION) 89
7.6 DNA MICROARRAY 90
7.6.1 THE INTRODUCTION OF DNA MICROARRAY HAS ACCELERATED GENE EXPRESSION AND DISEASE DIAGNOSIS 90
TABLE 14 DNA MICROARRAY TECHNOLOGY MARKET, BY REGION,
2019–2026 (USD MILLION) 90
7.7 OTHER TECHNOLOGIES 90
TABLE 15 OTHER TECHNOLOGIES MARKET, BY REGION, 2019–2026 (USD MILLION) 91
8 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 92
8.1 INTRODUCTION 93
TABLE 16 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 93
8.2 INFECTIOUS DISEASE DIAGNOSTICS 93
TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 94
TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE,
2019–2026 (USD MILLION) 94
8.2.1 COVID-19 95
8.2.1.1 The outbreak of the pandemic is a key factor driving market growth 95
TABLE 19 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 95
TABLE 20 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 96
8.2.2 HEPATITIS 96
8.2.2.1 The global prevalence of hepatitis is a key factor driving market growth 96
TABLE 21 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 96
TABLE 22 HEPATITIS DIAGNOSTICS MARKET, BY REGION,
2019–2026 (MILLION ASSAYS) 97
8.2.3 CT/NG 97
8.2.3.1 CT/NG infections are the most commonly prevalent STDs; key factor driving the market growth 97
TABLE 23 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 98
TABLE 24 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 98
8.2.4 HIV 98
8.2.4.1 The increasing number of blood transfusions & donations will drive the market growth for this segment 98
TABLE 25 HIV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 99
TABLE 26 HIV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 99
8.2.5 HAI 99
8.2.5.1 The rising burden of MRSA infections is a key factor driving the market growth for this segment 99
TABLE 27 HAI DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 100
TABLE 28 HAI DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 100
8.2.6 HPV 100
8.2.6.1 Technological advancements such as rapid HPV diagnostics to drive the market growth for this segment 100
TABLE 29 HPV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 101
TABLE 30 HPV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 101
8.2.7 TUBERCULOSIS 101
8.2.7.1 The increasing burden of TB globally to drive the market growth of this segment 101
TABLE 31 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 102
TABLE 32 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION,
2019–2026 (MILLION TESTS) 102
8.2.8 INFLUENZA 103
8.2.8.1 The rising focus on containing the spread of influenza drives the market growth for this segment 103
TABLE 33 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 103
TABLE 34 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 103
8.2.9 OTHER INFECTIOUS DISEASES 104
TABLE 35 OTHER INFECTIOUS DISEASES MARKET, BY REGION,
2019–2026 (USD MILLION) 104
8.3 ONCOLOGY TESTING 104
TABLE 36 ONCOLOGY TESTING MARKET, BY REGION, 2019–2026 (USD MILLION) 105
TABLE 37 ONCOLOGY TESTING MARKET, BY TYPE, 2019–2026 (USD MILLION) 105
8.3.1 BREAST CANCER 105
8.3.1.1 The increasing prevalence of breast cancer is a key driver for market growth 105
TABLE 38 ONCOLOGY TESTING MARKET FOR BREAST CANCER, BY REGION,
2019–2026 (USD MILLION) 106
8.3.2 COLORECTAL CANCER 106
8.3.2.1 The rising focus on the development of companion diagnostic assays drives the market growth 106
TABLE 39 ONCOLOGY TESTING MARKET FOR COLORECTAL CANCER, BY REGION,
2019–2026 (USD MILLION) 107
8.3.3 LUNG CANCER 107
8.3.3.1 Increasing research for lung cancer biomarkers to drive the market growth 107
TABLE 40 ONCOLOGY TESTING MARKET FOR LUNG CANCER, BY REGION,
2019–2026 (USD MILLION) 108
8.3.4 PROSTATE CANCER 108
8.3.4.1 Advancements in genomic technologies for the development of new biomarkers drive the market growth 108
TABLE 41 ONCOLOGY TESTING MARKET FOR PROSTATE CANCER, BY REGION,
2019–2026 (USD MILLION) 109
8.3.5 OTHER CANCERS 109
TABLE 42 OTHER CANCER DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 109
8.4 GENETIC TESTS 110
8.4.1 GENETIC TESTING ENABLES THE DIAGNOSIS OF VARIOUS DISEASES 110
TABLE 43 GENETIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION) 110
8.5 OTHER APPLICATIONS 110
TABLE 44 OTHER APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION) 111
9 MOLECULAR DIAGNOSTICS MARKET, BY END USER 112
9.1 INTRODUCTION 113
TABLE 45 MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 113
9.2 DIAGNOSTIC LABORATORIES 113
9.2.1 INCREASING OUTSOURCING OF ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVES MARKET GROWTH 113
TABLE 46 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2019–2026 (USD MILLION) 114
9.3 HOSPITALS AND CLINICS 114
9.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING MARKET GROWTH 114
TABLE 47 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS,
BY REGION, 2019–2026 (USD MILLION) 115
9.4 OTHER END USERS 115
TABLE 48 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION) 115
10 MOLECULAR DIAGNOSTICS MARKET, BY REGION 116
10.1 INTRODUCTION 117
TABLE 49 MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 117
10.2 NORTH AMERICA 117
FIGURE 25 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 118
TABLE 50 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 119
TABLE 51 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 119
TABLE 52 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 119
TABLE 53 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 120
TABLE 54 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION) 120
10.2.1 US 120
10.2.1.1 The increasing prevalence of infectious diseases and cancer is a key factor expected to drive market growth in the US 120
TABLE 55 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 121
TABLE 56 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 121
TABLE 57 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 122
TABLE 58 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 122
10.2.2 CANADA 122
10.2.2.1 The availability of funding for genomics research in Canada drives the market growth 122
TABLE 59 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 123
TABLE 60 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 123
TABLE 61 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 123
TABLE 62 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 124
10.3 EUROPE 124
TABLE 63 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 125
TABLE 64 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 125
TABLE 65 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 125
TABLE 66 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 126
TABLE 67 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany 126
TABLE 68 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 127
TABLE 69 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 127
TABLE 70 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 128
TABLE 71 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 128
10.3.2 ITALY 128
10.3.2.1 Adoption of advanced diagnostic technologies to drive market growth in Italy 128
TABLE 72 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 129
TABLE 73 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 129
TABLE 74 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 129
TABLE 75 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 130
10.3.3 FRANCE 130
10.3.3.1 Rising R&D expenditure in France to drive the market growth 130
TABLE 76 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 130
TABLE 77 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 131
TABLE 78 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 131
TABLE 79 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 131
10.3.4 RUSSIA 132
10.3.4.1 Increasing access to quality healthcare will support market growth in Russia 132
TABLE 80 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 132
TABLE 81 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 132
TABLE 82 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 133
TABLE 83 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 133
10.3.5 SPAIN 133
10.3.5.1 The increasing demand for genetic testing is expected to drive market growth in Spain 133
TABLE 84 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 134
TABLE 85 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
2019–2026 (USD MILLION) 134
TABLE 86 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 135
TABLE 87 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 135
10.3.6 UK 135
10.3.6.1 The increasing number of accredited diagnostic laboratories propels market growth for molecular diagnostics in the UK 135
TABLE 88 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 136
TABLE 89 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 136
TABLE 90 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 137
TABLE 91 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 137
10.3.7 REST OF EUROPE 137
TABLE 92 ROE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 138
TABLE 93 ROE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 138
TABLE 94 ROE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 138
TABLE 95 ROE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 139
10.4 ASIA PACIFIC 139
FIGURE 26 APAC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 140
TABLE 96 APAC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 141
TABLE 97 APAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 141
TABLE 98 APAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 141
TABLE 99 APAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 142
TABLE 100 APAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 142
10.4.1 CHINA 142
10.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth 142
TABLE 101 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 143
TABLE 102 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 143
TABLE 103 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 143
TABLE 104 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 145
10.4.2 JAPAN 145
10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan 145
TABLE 105 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 146
TABLE 106 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 146
TABLE 107 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 146
TABLE 108 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 147
10.4.3 INDIA 147
10.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth 147
TABLE 109 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 148
TABLE 110 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 148
TABLE 111 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 148
TABLE 112 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 149
10.4.4 AUSTRALIA 149
10.4.4.1 The prevalence of infectious diseases in Australia is a key driver for market growth 149
TABLE 113 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 149
TABLE 114 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 150
TABLE 115 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 150
TABLE 116 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 150
10.4.5 REST OF ASIA PACIFIC (ROAPAC) 151
TABLE 117 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 151
TABLE 118 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 152
TABLE 119 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 152
TABLE 120 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 152
10.5 LATIN AMERICA 153
TABLE 121 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 153
TABLE 122 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 153
TABLE 123 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 154
TABLE 124 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 154
TABLE 125 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 154
10.5.1 BRAZIL 155
10.5.1.1 Improving healthcare infrastructure in Brazil to drive the growth of the molecular diagnostics market 155
TABLE 126 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 155
TABLE 127 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 156
TABLE 128 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 156
TABLE 129 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 156
10.5.2 MEXICO 157
10.5.2.1 The improving accessibility and affordability of healthcare services to drive market growth for molecular diagnostics 157
TABLE 130 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 157
TABLE 131 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 158
TABLE 132 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 158
TABLE 133 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 158
10.5.3 REST OF LATIN AMERICA 159
TABLE 134 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 159
TABLE 135 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 159
TABLE 136 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 160
TABLE 137 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 160
10.6 MIDDLE EAST AND AFRICA 160
TABLE 138 MEA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 161
TABLE 139 MEA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 161
TABLE 140 MEA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 161
TABLE 141 MEA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 162
11 COMPETITIVE LANDSCAPE 163
11.1 OVERVIEW 163
11.2 KEY PLAYER STRATEGIES 163
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 164
11.4 MARKET SHARE ANALYSIS 165
FIGURE 28 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYERS (2020) 165
11.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY TECHNOLOGY 165
11.4.1.1 Polymerase Chain Reaction (PCR) 165
FIGURE 29 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 165
11.4.1.2 DNA Sequencing and NGS 166
FIGURE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING AND NGS, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 166
11.4.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT) 166
TABLE 142 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY KEY PLAYERS, 2020 166
11.4.1.4 In Situ Hybridization (ISH) 166
TABLE 143 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR ISH, BY KEY PLAYERS, 2020 166
11.4.2 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY APPLICATION 167
11.4.2.1 Infectious Disease Applications 167
TABLE 144 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET RANKING,
BY KEY PLAYERS, 2020 167
11.5 COMPETITIVE LEADERSHIP MAPPING 167
11.5.1 STARS 167
11.5.2 EMERGING LEADERS 167
11.5.3 PERVASIVE PLAYERS 168
11.5.4 PARTICIPANTS 168
FIGURE 31 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 168
11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME (2020) 169
11.6.1 PROGRESSIVE COMPANIES 169
11.6.2 STARTING BLOCKS 169
11.6.3 RESPONSIVE COMPANIES 169
11.6.4 DYNAMIC COMPANIES 169
FIGURE 32 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME, 2019 170
11.7 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS 171
FIGURE 33 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET 171
11.8 COMPETITIVE SCENARIO 171
FIGURE 34 MARKET EVALUATION MATRIX, 2018-2020 171
11.8.1 MOLECULAR DIAGNOSTICS: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2018 – MARCH 2021) 172
TABLE 145 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 172
11.8.2 MOLECULAR DIAGNOSTICS: DEALS (JANUARY 2018 – MARCH 2021) 172
TABLE 146 KEY DEALS 172
11.8.3 MOLECULAR DIAGNOSTICS: OTHER DEVELOPMENTS (JANUARY 2018 – MARCH 2021) 173
TABLE 147 OTHER KEY DEVELOPMENTS 173
12 COMPANY PROFILES 174
12.1 KEY PLAYERS 174
(Business overview, Products offered, Recent developments, SWOT analysis, Right to Win)*
12.1.1 F. HOFFMANN-LA ROCHE LTD. 174
TABLE 148 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 174
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 175
12.1.2 HOLOGIC, INC. 179
TABLE 149 HOLOGIC, INC.: BUSINESS OVERVIEW 179
FIGURE 36 HOLOGIC, INC.: COMPANY SNAPSHOT (2020) 180
12.1.3 BIOMÉRIEUX SA 184
TABLE 150 BIOMÉRIEUX SA: BUSINESS OVERVIEW 184
FIGURE 37 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 185
12.1.4 ABBOTT LABORATORIES 188
TABLE 151 ABBOTT LABORATORIES: BUSINESS OVERVIEW 188
FIGURE 38 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 189
12.1.5 QIAGEN 193
TABLE 152 QIAGEN: BUSINESS OVERVIEW 193
FIGURE 39 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 194
12.1.6 THERMO FISHER SCIENTIFIC INC. 199
TABLE 153 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 199
FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020) 200
12.1.7 ILLUMINA, INC. 202
TABLE 154 ILLUMINA, INC.: BUSINESS OVERVIEW 202
FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2020) 203
12.1.8 MYRIAD GENETICS INC. 206
TABLE 155 MYRIAD GENETICS INC.: BUSINESS OVERVIEW 206
FIGURE 42 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2019) 206
12.1.9 SIEMENS HEALTHINEERS AG 209
TABLE 156 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 209
FIGURE 43 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020) 210
12.1.10 DANAHER CORPORATION 212
TABLE 157 DANAHER CORPORATION: BUSINESS OVERVIEW 212
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2019) 212
12.1.11 GRIFOLS S.A. 215
TABLE 158 GRIFOLS S.A.: BUSINESS OVERVIEW 215
FIGURE 45 GRIFOLS S.A: COMPANY SNAPSHOT (2020) 215
12.1.12 AGILENT TECHNOLOGIES INC. 217
TABLE 159 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW 217
FIGURE 46 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2020) 218
12.1.13 BECTON, DICKINSON AND COMPANY 221
TABLE 160 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 221
FIGURE 47 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 222
12.1.14 DIASORIN S.P.A 224
TABLE 161 DIASORIN S.P.A: BUSINESS OVERVIEW 224
FIGURE 48 DIASORIN S.P.A: COMPANY SNAPSHOT (2019) 225
12.2 START UP/ SME PLAYERS 228
12.2.1 QUIDEL CORPORATION 228
TABLE 162 QUIDEL CORPORATION: BUSINESS OVERVIEW 228
FIGURE 49 QUIDEL CORPORATION: COMPANY SNAPSHOT (2019) 229
12.2.2 GENETIC SIGNATURES 232
TABLE 163 GENETIC SIGNATURES: BUSINESS OVERVIEW 232
FIGURE 50 GENETIC SIGNATURES: COMPANY SNAPSHOT (2020) 232
12.2.3 MDX HEALTH 234
TABLE 164 MDX HEALTH: BUSINESS OVERVIEW 234
FIGURE 51 MDX HEALTH: COMPANY SNAPSHOT (2019) 234
12.2.4 EXACT SCIENCES 236
TABLE 165 EXACT SCIENCES: BUSINESS OVERVIEW 236
FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2019) 236
12.2.5 BIOCARTIS NV 238
TABLE 166 BIOCARTIS NV: BUSINESS OVERVIEW 238
FIGURE 53 BIOCARTIS NV: COMPANY SNAPSHOT (2019) 238
12.2.6 TBG DIAGNOSTICS LTD. 241
TABLE 167 TBG DIAGNOSTICS LTD.: BUSINESS OVERVIEW 241
FIGURE 54 TBG DIAGNOSTICS LTD.: COMPANY SNAPSHOT (2019) 241
12.2.7 GENMARK DIAGNOSTICS INC. 243
TABLE 168 GENMARK DIAGNOSTICS INC.: BUSINESS OVERVIEW 243
FIGURE 55 GENMARK DIAGNOSTICS INC.: COMPANY SNAPSHOT (2019) 243
12.2.8 LUMINEX CORPORATION 245
TABLE 169 LUMINEX CORPORATION: BUSINESS OVERVIEW 245
FIGURE 56 LUMINEX CORPORATION: COMPANY SNAPSHOT (2019) 245
12.2.9 HTG MOLECULAR DIAGNOSTICS 247
TABLE 170 HTG MOLECULAR DIAGNOSTICS: BUSINESS OVERVIEW 247
FIGURE 57 HTG MOLECULAR DIAGNOSTICS: COMPANY SNAPSHOT (2019) 247
12.2.10 VELA DIAGNOSTICS 249
TABLE 171 VELA DIAGNOSTICS: BUSINESS OVERVIEW 249
12.2.11 AMOY DIAGNOSTICS CO. LTD. 252
TABLE 172 AMOY DIAGNOSTICS CO. LTD.: BUSINESS OVERVIEW 252
12.2.12 MOLBIO DIAGNOSTICS PVT. LTD. 255
TABLE 173 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW 255
12.2.13 ELITECHGROUP 257
TABLE 174 ELITECHGROUP: BUSINESS OVERVIEW 257
12.2.14 SAVYON DIAGNOSTICS LTD. 260
TABLE 175 SAVYON DIAGNOSTICS LTD.: BUSINESS OVERVIEW 260
12.2.15 ABACUS DIAGNOSTICA OY 262
TABLE 176 ABACUS DIAGNOSTICS OY: BUSINESS OVERVIEW 262
12.2.16 GENEOMBIO TECHNOLOGIES PVT LTD. 263
TABLE 177 GENEOMBIO TECHNOLOGIES PVT. LTD.: BUSINESS OVERVIEW 263
*Business overview, Products offered, Recent developments, SWOT analysis, Right to Win might not be captured in case of unlisted companies.
13 APPENDIX 265
13.1 INSIGHTS FROM INDUSTRY EXPERTS 265
13.2 DISCUSSION GUIDE 266
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 269
13.4 AVAILABLE CUSTOMIZATIONS 271
13.5 RELATED REPORTS 271
13.6 AUTHOR DETAILS 272



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の分子診断市場(~2026年):製品&サービス別(試薬、キット、PoC&卓上機器)、用途別(新型コロナウイルス感染症、肝炎、HAI、HIV、腫瘍、遺伝子検査)、技術別(PCR、NGS、ISH)、エンドユーザー別(病院、診断研究所)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆